| abstract |
Compounds (I) (A=2-furyl, substituted 2-furyl, 2-tetrahydrofuryl, substituted alkoxy or substituted phenoxyalkyl; B=B1, B2 or B3, but if B=B1 then A=substituted phenoxyalkyl) and their enantiomers, diastereoisomers and pharmaceutically acceptable salts are useful for the preparation of a medicament for the treatment of sexual dysfunction in males and females. Compounds II (I:B=B3, A ≠ 2-furyl) are novel and are claimed per se. Pharmaceutical compositions containing compounds II are also claimed, as are pharmaceutical compositions containing compounds I and one or more of a prostaglandin, a direct vasodilator and a 5 cGMP phosphodiesterase inhibitor (e.g. sildenafil). Compounds which bind to mammalian α1b adrenergic receptors with an affinity of at least about 10-8 M and which bind to mammalian α¿1b? adrenergic receptors with an affinity at least 10-fold higher than the affinity with which the compound binds to mammalian α1a or α1d α1L adrenergic receptors are also useful for the preparation of a medicament for the treatment of sexual dysfunction in males and females. A method of identifying such compounds is also disclosed and claimed. |